Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

Ruike Gao, Ying Zhang, Wei Hou, Jie Li, Guanghui Zhu, Xiaoxiao Zhang, Bowen Xu, Zhe Wu, Heping Wang, Ruike Gao, Ying Zhang, Wei Hou, Jie Li, Guanghui Zhu, Xiaoxiao Zhang, Bowen Xu, Zhe Wu, Heping Wang

Abstract

Background: Non-small-cell lung cancer (NSCLC) is usually diagnosed at an advanced stage, and chemotherapy is the main treatment for this disease. Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China. KLTi combined with chemotherapy could improve the short-term efficacy, quality of life, and performance status for NSCLC compared with chemotherapy alone. This trial aims to assess the long-term efficacy and safety of KLTi in combination with chemotherapy for the treatment of advanced NSCLC.

Methods: This will be an investigator-initiated multicenter open-label randomized controlled trial. We will randomly assign 334 eligible participants with stage IIIA-IV NSCLC to the treatment or control groups in a 1:1 ratio. Patients in both groups will be administered 4-6 cycles of first-line platinum-based double chemotherapy regimens. Patients with complete response, partial response, or stable disease after 4-6 cycles will receive non-platinum single-agent chemotherapy. Patients in the treatment group are to receive intravenous KLTi 200 ml per day continuously for 14 days, commencing on the first day of chemotherapy. The treatment will be discontinued at the time of disease progression or until unacceptable toxicity is noted. The follow-up will be conducted every 2 months until death, loss of follow-up, or 12 months from randomized enrollment. The primary outcome will be progression-free survival (PFS). The secondary outcomes will be the objective response rate, 1-year survival rate, quality of life, living ability, and blood lipids. The safety outcome will be the rate of adverse events.

Discussion: This study will be the first randomized controlled trial in which PFS is used as the primary outcome to test whether KLTi combined with first-line chemotherapy has superior efficacy and reduced toxicity compared to chemotherapy alone in advanced NSCLC. This will also be the first clinical study to observe the effects of KLTi on blood lipids.

Trial registration: ClinicalTrials.gov NCT03986528 . Prospectively registered on 30 May 2019.

Keywords: Chinese herbal medicine; Kanglaite injection; Non-small cell lung cancer; Progression-free survival; Protocol; Randomized controlled trial.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the study. KLTi, Kanglaite injection; PFS, progression-free survival; ORR, objective response rate

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi: 10.3322/caac.21565.
    1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi: 10.1056/NEJMoa0909530.
    1. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi: 10.1056/NEJMoa1214886.
    1. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc) 2015;51(1):7–20. doi: 10.1358/dot.2015.51.1.2250387.
    1. Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8(3):410–416. doi: 10.7150/jca.17144.
    1. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep. 2017;7(1):5532. doi: 10.1038/s41598-017-06002-8.
    1. Daga A, Ansari A, Patel S, Mirza S, Rawal R, Umrania V. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities. Asian Pac J Cancer Prev. 2015;16(10):4147–4156. doi: 10.7314/APJCP.2015.16.10.4147.
    1. Sankar K, Gadgeel SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20(8):647–661. doi: 10.1080/14737140.2020.1787156.
    1. Zhang S, Bai X, Shan F. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer. Int Immunopharmacol. 2020;80:106247. doi: 10.1016/j.intimp.2020.106247.
    1. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–iv237. doi: 10.1093/annonc/mdy275.
    1. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv1–i21. doi: 10.1093/annonc/mdx222.
    1. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res. 2007;13(11):3413–3422. doi: 10.1158/1078-0432.CCR-06-2923.
    1. Ota A, Gyawali B, Matsuoka A, Ando Y. Unconvincing benefit of combination therapy with gefitinib and pemetrexed in advanced non–small-cell lung cancer. J Clin Oncol. 2017;35(6):691–692. doi: 10.1200/JCO.2016.70.4148.
    1. Cheng Y, Murakami H, Yang P-C, He J, Nakagawa K, Kang JH, et al. Randomized phase ii trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016;34(27):3258–3266. doi: 10.1200/JCO.2016.66.9218.
    1. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (impress): overall survival and biomarker analyses. J Clin Oncol. 2017;35(36):4027–4034. doi: 10.1200/JCO.2017.73.9250.
    1. Hsu PC, Liu CY, Li SH, Huang SH, Wang CL, Kuo CH, et al. Efficacy of platinum-based combination chemotherapy in advanced lung adenocarcinoma harboring sensitive epidermal growth factor receptor (EGFR) mutations with acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI) Cancer Treat Res Commun. 2016;9:48–55. doi: 10.1016/j.ctarc.2016.07.005.
    1. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, et al. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018;125:273–281. doi: 10.1016/j.lungcan.2018.08.019.
    1. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi: 10.1056/NEJMoa1810865.
    1. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer. 2011;71(1):3–10. doi: 10.1016/j.lungcan.2010.08.022.
    1. Zhang Y, Wang XQ, Liu H, Liu J, Hou W, Lin HS. A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy. Zhonghua Zhong Liu Za Zhi. 2018;40(4):295–299.
    1. Li L, Liu W, Xu K. Effect of combination of syndrome differentiation depending treatment and chemotherapy on prognostic factors in treating mid-late patients with non-small call lung cancer. Zhongguo Zhong XI Yi Jie He Za Zhi. 2003;23(8):575–579.
    1. Zhou ZY, Xu L, Li HG, Tian JH, Jiao LJ, You SF, et al. Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial. J Integr Med. 2014;12(3):175–181. doi: 10.1016/S2095-4964(14)60028-5.
    1. Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo N, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4(6):297–307.
    1. Zhu L, Yang Z, Wang S, Tang Y. Kanglaite for treating advanced non-small-cell lung cancer: a systematic review. Zhongguo Fei Ai Za Zhi. 2009;12(3):208–215.
    1. Cao N, Ma X, Guo Z, Zheng Y, Geng S, Meng M, et al. Oral kanglaite injection (KLTI) attenuates the lung cancer-promoting effect of high-fat diet (HFD)-induced obesity. Oncotarget. 2016;7(38):61093–61106. doi: 10.18632/oncotarget.11212.
    1. Lu Y, Li C-S, Dong Q. Chinese herb related molecules of cancer-cell-apoptosis: a minireview of progress between Kanglaite injection and related genes. J Exp Clin Cancer Res. 2008;27(1):31. doi: 10.1186/1756-9966-27-31.
    1. Woo J-H, Li D, Wilsbach K, Orita H, Coulter J, Tully E, et al. Coix seed extract, a commonly used treatment for cancer in China, inhibits NFkappaB and protein kinase C signaling. Cancer Biol Ther. 2007;6(12):2005–2011. doi: 10.4161/cbt.6.12.5168.
    1. Pan P, Wu Y, Guo Z-Y, Wang R, Wang Y-J, Yuan Y-F. Antitumor activity and immunomodulatory effects of the intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma. J Ethnopharmacol. 2012;143(2):680–685. doi: 10.1016/j.jep.2012.07.025.
    1. Wen J, Yang T, Wang J, Ma X, Tong Y, Zhao Y. Kanglaite injection combined with chemotherapy versus chemotherapy alone for the improvement of clinical efficacy and immune function in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2020;2020:8586596.
    1. Huang X, Wang J, Lin W, Zhang N, Du J, Long Z, et al. Kanglaite injection plus platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of 27 RCTs. Phytomedicine. 2020;67:153154. doi: 10.1016/j.phymed.2019.153154.
    1. Liu X, Xu F, Wang G, Diao X, Li Y. Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: a systematic review and meta-analysis. Curr Ther Res Clin Exp. 2008;69(5):381–411. doi: 10.1016/j.curtheres.2008.10.004.
    1. Liu X, Yang Q, Xi Y, Yu K, Wang W, Zhao X, et al. Kanglaite injection combined with chemotherapy versus chemotherapy alone in the treatment of advanced non-small cell lung carcinoma. J Cancer Res Ther. 2014;10(Suppl 1):46–51.
    1. Yu F, Gao J, Zeng Y, Liu C-X. Effects of adlay seed oil on blood lipids and antioxidant capacity in hyperlipidemic rats. J Sci Food Agric. 2011;91(10):1843–1848. doi: 10.1002/jsfa.4393.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. National Comprehensive Cancer Network ® . NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer version 3. 2019. 2019.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365.
    1. Wan C, Meng Q, Yang Z, Tu X, Feng C, Tang X, et al. Validation of the simplified Chinese version of EORTC QLQ-C30 from the measurements of five types of inpatients with cancer. Ann Oncol. 2008;19(12):2053–2060. doi: 10.1093/annonc/mdn417.
    1. Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS) Support Care Cancer. 1999;7(3):140–148. doi: 10.1007/s005200050244.
    1. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;59(6):649–656. doi: 10.1097/00000421-198212000-00014.
    1. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634–656. doi: 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>;2-L.
    1. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432–1440. doi: 10.1016/S0140-6736(09)61497-5.
    1. Escudier B. Progression-free survival as a surrogate marker of overall survival: is it the good question? Cancer. 2011;117(12):2586–2587. doi: 10.1002/cncr.25955.
    1. Robinson AG, Booth CM, Eisenhauer EA. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice. Eur J Cancer. 2014;50(13):2303–2308. doi: 10.1016/j.ejca.2014.05.024.
    1. Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol. 2013;14(7):619–626. doi: 10.1016/S1470-2045(13)70158-X.
    1. Yoshida Y, Kaneko M, Narukawa M. Impact of advantage in tumor response on the correlation between progression-free survival and overall survival: meta-analysis of clinical trials in patients with advanced non-small cell lung cancer. Pharmaceut Med. 2021; 10.1007/s40290-021-00383-y.
    1. Asano K, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, et al. Impact of serum total cholesterol on the incidence of gastric cancer in a population-based prospective study: the Hisayama study. Int J Cancer. 2008;122(4):909–914. doi: 10.1002/ijc.23191.
    1. Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G, et al. Serum lipids and the risk of gastrointestinal malignancies in the Swedish AMORIS study. J Cancer Epidemiol. 2012;2012:792034. doi: 10.1155/2012/792034.
    1. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol. 2011;21(11):835–841. doi: 10.1016/j.annepidem.2011.07.007.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere